ArticleCancer research communications2024

A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors.

Rémi Vernet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.